Malaria is a devastating infection caused by protozoa of the genus Plasmodium. Drug resistance is widespread, no new chemical class of antimalarials has been introduced into clinical practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs. We screened nearly 2 million compounds in GlaxoSmithKline’s chemical library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 µM concentration. More than 8,000 also showed potent activity against the multidrug resistant strain Dd2. Most (82%) compounds originate from internal company projects and are new to the malaria community. Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host–pathogen interaction related targets. Chemical structures and associated data are hereby made public to encourage additional drug lead identification efforts and further research into this disease.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
World Health Organization. World malaria report. 〈http://www.who.int/malaria/publications/atoz/9789241563901/en/index.html〉 (2009)
Anstey, N. M., Russell, B., Yeo, T. W. & Price, R. N. The pathophysiology of vivax malaria. Trends Parasitol. 25, 220–227 (2009)
Ekland, E. H. & Fidock, D. A. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int. J. Parasitol. 38, 743–747 (2008)
Andriantsoanirina, V. et al. Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. Antimicrob. Agents Chemother. 53, 4588–4597 (2009)
Bonnet, M. et al. Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies. Malar. J. 8, 192 (2009)
Carrara, V. I. et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE 4, e4551 (2009)
Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29–40 (2007)
O'Brien, P. J. et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80, 580–604 (2006)
Xia, M. et al. Compound cytotoxicity profiling using quantitative high-throughput screening. Environ. Health Perspect. 116, 284–291 (2008)
Yuan, J. et al. Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum . Nature Chem. Biol. 5, 765–771 (2009)
Reed, M. B., Saliba, K. J., Caruana, S. R., Kirk, K. & Cowman, A. F. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum . Nature 403, 906–909 (2000)
Bemis, G. W. & Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887–2893 (1996)
Daylight Chemical Information Systems, Inc. Daylight theory manual. 〈http://www.daylight.com/dayhtml/doc/theory/index.html〉 (2008)
Johnson, M., Lajiness, M. & Maggiora, G. M. in Qsar: Quantitative structure-activity relationships in drug design (ed Fauchere, J. L.) 167–171 (Alan R. Liss, 1989)
Davis, A. M., Keeling, D. J., Steele, J., Tomkinson, N. P. & Tinker, A. C. Components of successful lead generation. Curr. Top. Med. Chem. 5, 421–439 (2005)
Köhler, S. et al. A plastid of probable green algal origin in apicomplexan parasites. Science 275, 1485–1489 (1997)
McFadden, G. I., Reith, M. E., Munholland, J. & Lang-Unnasch, N. Plastid in human parasites. Nature 381, 482 (1996)
Le Roch, K. G. et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 301, 1503–1508 (2003)
Bozdech, Z. et al. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum . PLoS Biol. 1, e5 (2003)
Wu, Y., Wang, X., Liu, X. & Wang, Y. Data-mining approaches reveal hidden families of proteases in the genome of malaria parasite. Genome Res. 13, 601–616 (2003)
Leroy, D. & Doerig, C. Drugging the Plasmodium kinome: The benefits of academia–industry synergy. Trends Pharmacol. Sci. 29, 241–249 (2008)
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002)
Anamika, S. N. & Krupa, A. A genomic perspective of protein kinases in Plasmodium falciparum . Proteins 58, 180–189 (2005)
Ward, P., Equinet, L., Packer, J. & Doerig, C. Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote. BMC Genomics 5, 79 (2004)
Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 26, 127–132 (2008)
Madeira, L. et al. Genome-wide detection of serpentine receptor-like proteins in malaria parasites. PLoS ONE 3, e1889 (2008)
Aurrecoechea, C. et al. PlasmoDB: A functional genomic database for malaria parasites. Nucleic Acids Res. 37, D539–D543 (2009)
Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, 673–675 (1976)
Makler, M. T. & Hinrichs, D. J. Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am. J. Trop. Med. Hyg. 48, 205–210 (1993)
Zhang, J. H., Chung, T. D. Y. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67–73 (1999)
Desjardins, R. E., Canfield, C. J., Haynes, J. D. & Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16, 710–718 (1979)
Goodman, C. D., Su, V. & McFadden, G. I. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum . Mol. Biochem. Parasitol. 152, 181–191 (2007)
Ramya, T. N. C., Mishra, S., Karmodiya, K., Surolia, N. & Surolia, A. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum . Antimicrob. Agents Chemother. 51, 307–316 (2007)
Fidock, D. A., Rosenthal, P. J., Croft, S. L., Brun, R. & Nwaka, S. Antimalarial drug discovery: Efficacy models for compound screening. Nature Rev. Drug Discov. 3, 509–520 (2004)
Aureus Pharma. AurSCOPE database. 〈http://www.aureus-pharma.com/Pages/Products/Aurscope.php〉 (2004)
Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389–3402 (1997)
Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673–4680 (1994)
Felsentein, J. Phylip (phylogenetic inference package) v3.67. Department of Genetics, University of Washington 〈http://evolution.genetics.washington.edu/phylip.html〉.
Huson, D. H. et al. Dendroscope: An interactive viewer for large phylogenetic trees. BMC Bioinformatics 8, 460 (2007)
We thank S. Peregrina and S. Prats for technical assistance, and D. Jiménez-Alfaro for supplying compounds pre-dispensed in microtitre plates. We thank P. Vallance and R. Keenan for organising support for this work, R. Macarron and J. Luengo for developing the IFI index and getting the chemistry data ready for publication, together with J. M. Fiandor, S. Chakravorty and members of GSK’s Chemistry Council. J. Lewis, A. Clow, J. Overington and M. Davies were instrumental in the uploading and formatting of the data. We also thank N. Cammack, P. Sanseau and J. Burrows for critically commenting on the manuscript. The support and funding of Medicines for Malaria Venture is gratefully acknowledged.
The authors declare no competing financial interests.
Chemical structures and data described have been deposited at EBI (http://www.ebi.ac.uk/chemblntd).
This file contains Supplementary Figures 1-3 with legends and Supplementary Tables 3-5. (PDF 675 kb)
This table contains an annotated list of all positives from the P. falciparum screen. Structures are shown as "SMILES" codes. (XLS 3451 kb)
This table shows compounds in TCAMS with literature references on their mode of action. (XLS 437 kb)
The file contains the multiple kinase sequence alignment. This file was added on 2 June 2010. (TXT 173 kb)
About this article
Cite this article
Gamo, F., Sanz, L., Vidal, J. et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305–310 (2010). https://doi.org/10.1038/nature09107
Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials
ACS Infectious Diseases (2020)
Cell Chemical Biology (2020)
Insect Biochemistry and Molecular Biology (2020)
An Antiparasitic Compound from the Medicines for Malaria Venture Pathogen Box Promotes Leishmania Tubulin Polymerization
ACS Infectious Diseases (2020)
Developments in drug design strategies for bromodomain protein inhibitors to target Plasmodium falciparum parasites
Expert Opinion on Drug Discovery (2020)